Full text

Turn on search term navigation

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Bisphenol A (BPA) is a ubiquitous synthetic compound used as a monomer in the production of polycarbonate plastics and epoxy resins. Even at low doses, BPA has been associated with the molecular progression of diseases such as obesity, metabolic syndrome, and hormone-regulated cancers due to its activity as an endocrine-disrupting chemical (EDC). Consequently, the use of BPA has been regulated worldwide by different health agencies. BPA structural analogs such as bisphenol S and bisphenol F (BPS and BPF) have emerged as industrial alternatives, but their biological activity in the molecular progression of cancer remains unclear. Prostate cancer (PCa) is a hormone-dependent cancer, and the role of BPA structural analogs in PCa progression is still undescribed. In this work, we use an in vitro model to characterize the transcriptomic effect of low-concentration exposure to bisphenol A, S, or F in the two main stages of the disease: androgen dependency (LNCaP) and resistance (PC-3). Our findings demonstrated that the low concentration exposure to each bisphenol induced a differential effect over PCa cell lines, which marks the relevance of studying the effect of EDC compounds through all the stages of the disease.

Details

Title
Transcriptome-Wide Analysis of Low-Concentration Exposure to Bisphenol A, S, and F in Prostate Cancer Cells
Author
Cortés-Ramírez, Sergio A 1   VIAFID ORCID Logo  ; Salazar, Ana M 2 ; Sordo, Monserrat 2 ; Ostrosky-Wegman, Patricia 2   VIAFID ORCID Logo  ; Morales-Pacheco, Miguel 1   VIAFID ORCID Logo  ; Cruz-Burgos, Marian 1   VIAFID ORCID Logo  ; Losada-García, Alberto 1 ; Rodríguez-Martínez, Griselda 1 ; González-Ramírez, Imelda 3 ; Vazquez-Santillan, Karla 4   VIAFID ORCID Logo  ; González-Covarrubias, Vanessa 5   VIAFID ORCID Logo  ; Maldonado-Lagunas, Vilma 6   VIAFID ORCID Logo  ; Rodríguez-Dorantes, Mauricio 1   VIAFID ORCID Logo 

 Laboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico; [email protected] (S.A.C.-R.); [email protected] (M.M.-P.); [email protected] (M.C.-B.); [email protected] (A.L.-G.); [email protected] (G.R.-M.) 
 Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Mexico City 70228, Mexico; [email protected] (A.M.S.); [email protected] (P.O.-W.) 
 Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City 04960, Mexico; [email protected] 
 Laboratorio de Innovación en Medicina de Precisión, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico; [email protected] 
 Laboratorio de Farmacogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico; [email protected] 
 Laboratorio de Epigenética, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico 
First page
9462
Publication year
2023
Publication date
2023
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2824008278
Copyright
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.